In the rare cases of HER2-positive and triple-negative MaBCs, targeted therapies with anti-HER2 and anti-PD1 monoclonal antibodies, respectively, follow the same treatment recommendations for women with these tumor subtypes (26). This evidence concerns the gene ERBB2 and neoplasm.